Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34709849.
- Also identified by DOI 10.1200/JCO.21.01910.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<i>The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in</i> Journal of Clinical Oncology, <i>to patients seen in their own clinical practice</i>.
Medical subject headings
- Antineoplastic Agents, Hormonal
- Breast Neoplasms
- Drug Resistance, Neoplasm
- Mastectomy
- Receptors, Estrogen
- Receptors, Progesterone